Ozempic and Hair Loss: What the Research Actually Shows

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become the most prescribed weight-loss medications in history. Tens of millions of people are on these drugs, and a growing number are noticing something unexpected: their hair is falling out. Clinical trial data confirms the link. Wilding et al. (2021) in The New England Journal of Medicine reported alopecia in 3% of semaglutide patients versus 1% on placebo. Jastreboff et al. (2022) in the same journal documented 5.7% alopecia in the highest tirzepatide dose group. These aren't Reddit anecdotes. They're peer-reviewed numbers from randomized controlled trials.

Track your hair through GLP-1 treatment

BaldingAI captures weekly progress photos with guided positioning so you can see whether shedding is temporary or something to discuss with your doctor.

Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.

Start Tracking In BaldingAITry free tools or compare the app first

How common is hair loss on GLP-1 drugs?

Every major GLP-1 weight-loss trial has recorded alopecia at rates significantly above placebo, and the numbers reveal a clear dose-dependent pattern.

Semaglutide (Ozempic/Wegovy). The STEP 1 trial enrolled 1,961 adults and randomized them to semaglutide 2.4 mg weekly or placebo. Over 68 weeks, 3% of semaglutide patients reported alopecia versus 1% on placebo (Wilding et al., 2021, NEJM). At lower diabetes doses (0.25-1.0 mg), hair loss reports are less frequent, supporting the idea that shedding is driven by weight loss rate rather than a direct drug effect on follicles.

Tirzepatide (Mounjaro/Zepbound). The SURMOUNT-1 trial randomized 2,539 adults to tirzepatide (5 mg, 10 mg, or 15 mg) or placebo. Alopecia rates were 3.0% at 5 mg, 5.0% at 10 mg, and 5.7% at 15 mg, versus 1.0% on placebo (Jastreboff et al., 2022, NEJM). The dose-response pattern is striking: higher doses produce faster weight loss and more shedding. Tirzepatide is a dual GIP/GLP-1 agonist that produces greater average weight loss than semaglutide, which aligns with a weight-loss-driven mechanism.

A 5.7% incidence rate means roughly 1 in 18 people on the highest tirzepatide dose reported clinically noticeable hair shedding. With tens of millions of prescriptions written globally, the absolute number of affected users is substantial.

Why GLP-1 drugs cause hair shedding

Semaglutide and tirzepatide don't directly attack hair follicles. The shedding is caused by telogen effluvium triggered by rapid weight loss. This is the same mechanism behind hair loss after bariatric surgery, crash diets, and severe caloric restriction. The drug is the means of weight loss; the hair loss is a downstream effect of losing significant body weight quickly.

Hair grows in cycles: anagen (active growth, 2-7 years), catagen (transition, 2-3 weeks), and telogen (resting, 2-3 months). Normally 85-90% of hair is in anagen. When the body experiences significant metabolic stress (losing more than 10% of body weight over a few months), it diverts resources from non-essential functions like hair growth. A larger percentage of follicles gets prematurely shifted from anagen into telogen. Two to four months later, those hairs fall out.

The bariatric surgery literature confirms this. Villareal et al. (2005) in the American Journal of Clinical Nutrition documented telogen effluvium in gastric bypass patients who lost weight rapidly. The pattern is identical: onset 2-4 months after rapid loss begins, diffuse shedding, and gradual recovery once weight stabilizes. The rate of loss matters more than the total amount. Losing 15 kg in 4 months produces far more follicular stress than the same loss over 12 months.

GLP-1 drugs compound this by aggressively suppressing appetite. Reduced food intake creates risk for protein deficiency (hair is almost entirely keratin, a protein) and micronutrient gaps in iron, zinc, and vitamin D, all of which play documented roles in the hair growth cycle. The caloric deficit, nutrient insufficiency, and metabolic shift combine into a potent telogen effluvium trigger.

The telogen effluvium timeline on GLP-1s

GLP-1-induced telogen effluvium follows a predictable trajectory. Understanding the phases helps separate normal recovery from situations that need medical attention.

Onset: 2-4 months after starting treatment. Most people notice increased shedding 8-16 weeks after starting. The delay exists because follicles shifted into telogen during the initial rapid weight loss still need 2-3 months to complete the resting phase. By month 3-4, many patients have already lost significant weight and feel great about the medication, which makes the sudden clumps of hair feel contradictory and alarming.

Peak shedding: 3-5 months into treatment. The worst shedding corresponds to the period of fastest active weight loss. During this phase, losing 200-300 hairs per day is common compared to the normal 50-100 (American Academy of Dermatology baseline). Hair feels noticeably thinner, ponytails shrink, and more scalp becomes visible at the part line.

Stabilization: 6-8 months, if weight stabilizes. As weight loss decelerates, the trigger for ongoing follicular stress diminishes. Shedding gradually decreases. If you reach your target weight or a maintenance dose and your weight plateaus, shedding typically normalizes within a few months. The key variable is when rapid weight loss stops. If you continue losing fast for 12 months, the shedding window extends accordingly.

Regrowth: 6-12 months after stabilization. Follicles cycle back into anagen and new hairs appear as short, fine regrowth along the part line and hairline. Hair grows approximately half an inch per month, so it takes 6-12 months before new growth contributes meaningfully to density. Full visual recovery can take 12-18 months from weight stabilization.

Risk factors that increase shedding on GLP-1s

Not everyone on semaglutide or tirzepatide sheds hair. Several factors determine whether you fall into the 3-6% who do.

Faster rate of weight loss. The single biggest predictor. The SURMOUNT-1 dose-response data makes this clear: higher doses produce faster loss and more shedding. Patients losing more than 1-1.5 kg per week face substantially higher telogen effluvium risk. Your prescriber can adjust dose titration speed to moderate this, though the trade-off is slower weight loss progress.

Pre-existing nutritional deficiencies. If your iron, ferritin, zinc, or vitamin D levels were already borderline, reduced caloric intake from appetite suppression can push them into clinically deficient territory. Trost et al. (2006) in the Journal of the American Academy of Dermatology concluded that ferritin levels below 40 ng/mL are associated with increased telogen effluvium risk. Someone starting GLP-1 therapy with a ferritin of 35 ng/mL who then eats 40% fewer calories has very little buffer.

Insufficient protein intake. When daily caloric intake drops to 800-1,200 calories (common on semaglutide), hitting the recommended 0.8-1.0 g protein per kilogram of body weight becomes very difficult without deliberate planning. Protein insufficiency impairs keratin synthesis and accelerates the shift into telogen.

Concurrent stress. Telogen effluvium triggers are additive. Psychological stress, sleep deprivation, a recent illness, or a major life change each independently shift follicles into telogen. Stack enough triggers and the total percentage pushed into resting phase becomes clinically visible.

What to track while on semaglutide or tirzepatide

Structured tracking transforms GLP-1 hair loss from an anxiety-producing mystery into a dataset you can evaluate objectively.

Weekly progress photos. Capture four views every week under identical conditions: front hairline, right temple, left temple, and crown from directly overhead. Same lighting, same hair state (dry or wet, pick one), same position. Comparing week 12 to week 1 is far more reliable than your memory of how your hair "used to feel."

Wash-day shedding counts. Collect shed hairs from the drain on wash days and estimate the count. Exact numbers don't matter. The trend does: are counts going up, holding steady, or declining? Wash-day counts are more reliable than daily counts because they accumulate 2-3 days of natural shedding, smoothing out fluctuations.

Weight loss rate. Log weekly weigh-ins alongside your hair data. If shedding peaks during the weeks of fastest weight loss and then decreases as the rate slows, that pattern strongly supports telogen effluvium. If shedding continues after weight stabilizes, that divergence is your signal to see a dermatologist.

Nutritional markers. Get baseline bloodwork before starting your GLP-1 or as soon as possible. Key markers: ferritin (target above 40 ng/mL), serum iron, zinc, 25-hydroxyvitamin D (target 30-50 ng/mL), total protein and albumin, and thyroid panel (TSH, free T4). Recheck at 3 and 6 months. Tracking these alongside hair data helps identify correctable nutritional causes.

Nutritional support during GLP-1 treatment

You cannot supplement your way out of rapid-weight-loss telogen effluvium. But you can reduce its severity by ensuring your body has the raw materials for hair growth.

Protein is priority one. Aim for 0.8-1.0 g per kilogram of body weight daily. A 90 kg person needs 72-90 g. On 1,000 calories (common on semaglutide), that requires deliberate planning and often supplemental protein shakes. This is the single most actionable intervention for reducing GLP-1-related shedding.

Iron and ferritin. If ferritin is below 40 ng/mL, discuss supplementation with your doctor. Don't self-supplement at high doses without testing, as iron overload carries serious risks. A ferritin above 70 ng/mL provides a more comfortable buffer during active weight loss.

Zinc. Karashima et al. (2012) in the Journal of Clinical and Diagnostic Research found significantly lower serum zinc in telogen effluvium patients versus controls. If bloodwork confirms low zinc, 15-30 mg daily is standard. Don't exceed 40 mg without medical supervision, as excess zinc interferes with copper absorption.

Vitamin D. Rasheed et al. (2013) in the Journal of Cosmetic Dermatology found vitamin D deficiency was significantly more common in women with telogen effluvium. Target 30-50 ng/mL. If deficient, 2,000-4,000 IU daily is typical.

Get bloodwork before you start. Without a baseline, you can't tell whether a low ferritin at month 4 is from reduced eating or was already low. Ask your prescriber for a panel that includes ferritin, serum iron, zinc, vitamin D, thyroid function, and total protein.

When to see a dermatologist

Most GLP-1-related telogen effluvium resolves without intervention once weight stabilizes. But specific warning signs indicate you need a professional evaluation.

Shedding continues 9+ months after weight stabilization. The key word is "stabilization," not "starting the drug." If your weight has been stable for 6-9 months and shedding hasn't normalized, the condition may have transitioned into chronic telogen effluvium or another process may be contributing. A dermatologist can perform trichoscopy to evaluate follicle health.

A pattern develops. Telogen effluvium thins hair diffusely across the entire scalp. If temples recede, the crown thins preferentially, or the central part widens while sides and back stay full, that geographic selectivity indicates androgenetic alopecia. Rapid weight loss may have unmasked latent pattern loss. This distinction matters because pattern loss requires treatment (finasteride, minoxidil) while telogen effluvium resolves on its own.

Patchy bald spots appear. Round or oval patches of smooth hairless skin are not telogen effluvium. They may indicate alopecia areata, an autoimmune condition requiring a completely different treatment pathway.

You want to rule out other causes. Thyroid dysfunction, iron deficiency anemia, and autoimmune conditions can all worsen shedding alongside GLP-1 use. Bring your tracking data to the appointment. Weekly photos, shedding counts, and weight-loss logs compress months of information into evidence a clinician can evaluate in minutes.

The bottom line: data over panic

GLP-1-related hair loss is real, it's documented in every major clinical trial, and it affects a meaningful percentage of users. But for the vast majority of people, it's temporary telogen effluvium driven by rapid weight loss rather than permanent damage to hair follicles. The same mechanism has been observed for decades after bariatric surgery and crash diets. The hair grows back once the trigger resolves.

The problem isn't the shedding itself. The problem is the uncertainty. Not knowing whether your hair is on a recovery trajectory or a progressive decline is what keeps people anxious, scanning their pillows every morning, and catastrophizing every shower. Structured tracking eliminates that uncertainty. Weekly photos give you a visual timeline. Wash-day counts give you a numerical trend. Weight-loss correlation gives you a causal framework. Nutritional bloodwork gives you actionable interventions.

If you're on a GLP-1 and noticing more hair in the drain, start tracking now. Capture your baseline photos today. Record your first wash-day count this week. Get your bloodwork done this month. Six months from now you'll have a clear, documented trend that either confirms your hair is recovering normally or gives a dermatologist exactly the information they need to help you. Either way, data beats dread.